Enrique M Ocio

Enrique M Ocio

UNVERIFIED PROFILE

Are you Enrique M Ocio?   Register this Author

Register author
Enrique M Ocio

Enrique M Ocio

Publications by authors named "Enrique M Ocio"

Are you Enrique M Ocio?   Register this Author

75Publications

2498Reads

19Profile Views

Induction Therapy for Newly Diagnosed Multiple Myeloma.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:e176-e186. Epub 2019 May 17.

4 Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_238527DOI Listing
January 2019

Aggressive primary cutaneous CD30+ lymphoproliferative disorder in an organ transplant recipient in sustained complete remission with brentuximab vedotin.

Int J Dermatol 2018 Dec 7;57(12):e153-e155. Epub 2018 Sep 7.

Departamento de Dermatología, Hospital Universitario de Salamanca, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14214DOI Listing
December 2018

Treatment for patients with newly diagnosed multiple myeloma in 2015.

Blood Rev 2015 Nov 12;29(6):387-403. Epub 2015 Jun 12.

Clínica Universidad de Navarra/Centro de Investigación Médica Aplicada (CIMA), Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2015.06.001DOI Listing
November 2015

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.

Oncotarget 2014 Sep;5(18):8284-305

Centro de Investigación del Cáncer, IBMCC (Universidad de Salamanca-CSIC), Salamanca, Spain. Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain. Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226683PMC
http://dx.doi.org/10.18632/oncotarget.2058DOI Listing
September 2014

Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.

Clin Cancer Res 2014 Mar 31;20(6):1542-54. Epub 2014 Jan 31.

Authors' Affiliations: Centro de Investigación del Cáncer, IBMCC (Universidad de Salamanca-CSIC); Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León; Hospital Universitario de Salamanca-IBSAL, Salamanca; Laboratorio de Imagen del Cáncer, Centro de Investigación Médica Aplicada, Universidad de Navarra, Pamplona, Spain; MGH Cancer Center, Massachusetts General Hospital; Dana-Farber Cancer Institute, Harvard Medical School, Boston; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA; and Departments of Cell Biology and Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1657DOI Listing
March 2014

Future agents and treatment directions in multiple myeloma.

Expert Rev Hematol 2014 Feb 18;7(1):127-41. Epub 2013 Dec 18.

Department of Hematology, University Hospital of Salamanca-IBSAL, IBMCC (USAL-CSIC),University Hospital & Cancer Research Center, P. San Vicente, 58-182, 37007 Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2014.858595DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157182PMC
February 2014

Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.

Mol Cancer Ther 2014 Feb 15;13(2):504-16. Epub 2014 Jan 15.

Corresponding Author: Atanasio Pandiella, Instituto de Biología Molecular y Celular del Cáncer, Campus Miguel de Unamuno, 37007 Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0022DOI Listing
February 2014

Novel generation of agents with proven clinical activity in multiple myeloma.

Semin Oncol 2013 Oct;40(5):618-33

Haematology Department, University Hospital of Salamanca, Cancer Research Center (IBMCC-CSIC), University of Salamanca, Institute of Biomedical Research of Salamanca (IBSAL), Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2013.07.005DOI Listing
October 2013

Potent antimyeloma activity of a novel ERK5/CDK inhibitor.

Clin Cancer Res 2013 May 26;19(10):2677-87. Epub 2013 Mar 26.

Instituto de Biología Molecular y Celular del Cáncer, CSIC-IBSAL-Universidad de Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-2118DOI Listing
May 2013

RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications.

Invest New Drugs 2013 Feb 7;31(1):200-5. Epub 2012 Jul 7.

Centro de Investigación del Cáncer, IBMCC (Universidad de Salamanca-CSIC), Campus Miguel de Unamuno, Avda. Coimbra s/n, 37007 Salamanca, Spain.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-012-9845-3
Publisher Site
http://dx.doi.org/10.1007/s10637-012-9845-3DOI Listing
February 2013

Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs.

Expert Opin Investig Drugs 2012 Aug 24;21(8):1075-87. Epub 2012 May 24.

University of Salamanca, University Hospital & Cancer Research Center, Department of Hematology, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2012.691164DOI Listing
August 2012

CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype.

Haematologica 2012 Jul 7;97(7):1110-4. Epub 2012 Feb 7.

Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer/Centro de Superior de Investigaciones Científicas-Universidad de Salamanca, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://www.haematologica.org/cgi/doi/10.3324/haematol.2011.0
Publisher Site
http://dx.doi.org/10.3324/haematol.2011.057372DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396685PMC
July 2012

Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometry.

Clin Lymphoma Myeloma Leuk 2011 Feb;11(1):93-5

University Hospital of Salamanca, Cancer Research Center (IBMCC-CSIC), University of Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLML.2011.n.017DOI Listing
February 2011

The DAC system and associations with multiple myeloma.

Invest New Drugs 2010 Dec 1;28 Suppl 1:S28-35. Epub 2010 Dec 1.

University Hospital of Salamanca, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-010-9589-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003792PMC
December 2010

Novel treatment regimens for Waldenström's macroglobulinemia.

Expert Rev Hematol 2010 Jun;3(3):339-50

University Hospital of Salamanca, Universidad de Salamanca-Consejo Superior de Investigaciones Científicas, Paseo de San Vicente 58-182, Salamanca 37007, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.10.19DOI Listing
June 2010

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.

Lancet Oncol 2008 Dec;9(12):1157-65

Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(08)70304-8DOI Listing
December 2008

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

Cancer Res 2006 Jun;66(11):5781-9

Centro de Investigación del Cáncer, Consejo Superior de Investigaciones Cientificas, Universidad de Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-05-4186DOI Listing
June 2006

Immunophenotypic and cytogenetic comparison of Waldenstrom's macroglobulinemia with splenic marginal zone lymphoma.

Clin Lymphoma 2005 Mar;5(4):241-5

Hematology Service, Hospital Universitario de Salamanca, Paseo san Vicente 58-182, 37007 Salamanca, Spain.

View Article

Download full-text PDF

Source
March 2005

Cell cycle analysis of Waldenstrom's macroglobulinemia.

Clin Lymphoma 2005 Mar;5(4):250-2

Hematology Service, Hospital Universitario de Salamanca, Paseo san Vicente 58-182, 37007 Salamanca, Spain.

View Article

Download full-text PDF

Source
March 2005